{
    "nct_id": "NCT06052059",
    "official_title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants With Moderately to Severely Active Ulcerative Colitis",
    "inclusion_criteria": "* Has had ulcerative colitis (UC) (from onset of symptoms) for at least 3 months before randomization\n* Has moderately to severely active UC\n* Weight ≥40 kg\n* Satisfies at least 1 of the following criteria:\n\n  * Has had an inadequate response or loss of response to 1 or more protocol-specified UC treatments\n  * Protocol specified corticosteroid dependence\n  * Has been intolerant to 1 or more protocol-specified UC treatments\n* Is on treatment with any protocol-specified drugs during the study and meets drug stabilization requirements, as applicable\n* Adolescent participants ≥16 and <18 years of age can participate if approved by the country or regulatory/health authority\n* A participant assigned female sex at birth is eligible to participate if not pregnant or breastfeeding and Is not a participant of childbearing potential (POCBP); or is a POCBP and uses an acceptable contraceptive method, or is abstinent from penile-vaginal intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), has a negative highly sensitive pregnancy test (urine or serum) as required by local regulations within 24 hours (for a urine test) or 72 hours (for a serum test) before the first dose of study intervention, medical history, menstrual history, and recent sexual activity has been reviewed by the investigator to decrease the risk for inclusion of a POCBP with an early undetected pregnancy\nHealthy volunteers allowed\nMust have minimum age of 16 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* Has a diagnosis of Crohn's Disease (CD) or indeterminate colitis (inflammatory bowel disease (IBD)-undefined) or other types of colitis or enteritis that may confound efficacy assessment.\n* Has a current diagnosis of fulminant colitis and/or toxic megacolon\n* Has UC limited to the rectum (i.e, must have evidence of UC extending beyond the rectosigmoid junction, which is ~10 cm from the anal margin)\n* Has a current or impending need for colostomy or ileostomy\n* Has had a total proctocolectomy or partial colectomy\n* Has received fecal microbial transplantation within 4 weeks before randomization\n* Has had UC exacerbation requiring hospitalization within 2 weeks before screening\n* Has prior or current evidence of definite colonic dysplasia except for low-grade dysplasia that has been completely removed\n* Has any active or serious infections without resolution after adequate treatment\n* Has had cytomegalovirus infection that resolved less than 4 weeks before screening\n* Has a transplanted organ which requires continued immunosuppression\n* Has a history of cancer (except fully treated non-melanoma skin cell cancers or cervical carcinoma in situ after complete surgical removal) within the last 5 years\n* Is known to be infected with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)\n* Has evidence of active tuberculosis (TB), latent TB not successfully treated (per local guidelines), or inadequately treated TB (for participants with history of TB)\n* Has confirmed or suspected COVID-19\n* Has a history of drug or alcohol abuse within 6 months prior to screening\n* Has had major surgery within 3 months before screening or has a major surgery planned during the study\n* Is currently receiving or is planning to receive total parenteral nutrition at any time during study treatment\n* Has received UC-related antibiotics and has not been on stable doses for at least 14 days before randomization or has discontinued these medications within 14 days of randomization\n* Requires treatment with a therapy that does not adhere to the protocol-specified guidance parameters\n* Has received protocol-specified prohibited medications\n* Has had prior exposure to tulisokibart or another anti-tumor necrosis factor-like cytokine 1A (TL1A) antibody",
    "miscellaneous_criteria": ""
}